Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar.
| Author | Chemaitelly, Hiam |
| Author | Ayoub, Houssein H |
| Author | AlMukdad, Sawsan |
| Author | Coyle, Peter |
| Author | Tang, Patrick |
| Author | Yassine, Hadi M |
| Author | Al-Khatib, Hebah A |
| Author | Smatti, Maria K |
| Author | Hasan, Mohammad R |
| Author | Al-Kanaani, Zaina |
| Author | Al-Kuwari, Einas |
| Author | Jeremijenko, Andrew |
| Author | Kaleeckal, Anvar Hassan |
| Author | Latif, Ali Nizar |
| Author | Shaik, Riyazuddin Mohammad |
| Author | Abdul-Rahim, Hanan F |
| Author | Nasrallah, Gheyath K |
| Author | Al-Kuwari, Mohamed Ghaith |
| Author | Butt, Adeel A |
| Author | Al-Romaihi, Hamad Eid |
| Author | Al-Thani, Mohamed H |
| Author | Al-Khal, Abdullatif |
| Author | Bertollini, Roberto |
| Author | Abu-Raddad, Laith J |
| Available date | 2022-06-12T10:19:34Z |
| Publication Date | 2022-06-02 |
| Publication Name | nature communications |
| Identifier | http://dx.doi.org/10.1038/s41467-022-30895-3 |
| Citation | Chemaitelly, H., Ayoub, H.H., AlMukdad, S. et al. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. Nat Commun 13, 3082 (2022). https://doi.org/10.1038/s41467-022-30895-3 |
| Abstract | SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted a matched, test-negative, case-control study to estimate duration of protection of the second and third/booster doses of mRNA COVID-19 vaccines against BA.1 and BA.2 infections in Qatar. BNT162b2 effectiveness was highest at 46.6% (95% CI: 33.4-57.2%) against symptomatic BA.1 and at 51.7% (95% CI: 43.2-58.9%) against symptomatic BA.2 infections in the first three months after the second dose, but declined to ~10% or below thereafter. Effectiveness rebounded to 59.9% (95% CI: 51.2-67.0%) and 43.7% (95% CI: 36.5-50.0%), respectively, in the first month after the booster dose, before declining again. Effectiveness against COVID-19 hospitalization and death was 70-80% after the second dose and >90% after the booster dose. mRNA-1273 vaccine protection showed similar patterns. mRNA vaccines provide comparable, moderate, and short-lived protection against symptomatic BA.1 and BA.2 Omicron infections, but strong and durable protection against COVID-19 hospitalization and death. |
| Sponsor | We acknowledge the many dedicated individuals at Hamad Medical Corporation, the Ministry of Public Health, the Primary Health Care Corporation, the Qatar Biobank, Sidra Medicine, and Weill Cornell Medicine—Qatar for their diligent efforts and contributions to make this study possible. The authors are grateful for support from the Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine-Qatar, as well as for support provided by the Ministry of Public Health, Hamad Medical Corporation, and Sidra Medicine. The authors are also grateful for the Qatar Genome Program and Qatar University Biomedical Research Center for institutional support for the reagents needed for the viral genome sequencing. Statements made herein are solely the responsibility of the authors. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the article. |
| Language | en |
| Publisher | Nature Research |
| Subject | Epidemiology Viral infection |
| Type | Article |
| ESSN | 2041-1723 |
Files in this item
This item appears in the following Collection(s)
-
Biomedical Research Center Research [738 items ]
-
Biomedical Sciences [723 items ]
-
COVID-19 Research [832 items ]
-
Mathematics, Statistics & Physics [736 items ]
-
Public Health [423 items ]